| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 16, 2025 | A New Dawn in Clinical Trials: Innovations in Immunotherapy and Dengue Treatment | The world of medicine is a battlefield. Every day, researchers and companies fight against diseases that plague humanity. Two recent developments shine a light on this ongoing struggle: SynAct Pharma’s resomelagon for dengue and Elicera The... |
| Apr 14, 2025 | BioStock: SynAct Pharma’s resomelagon under clinical evaluation for dengue | BioStock: SynAct Pharma’s resomelagon under clinical evaluation for dengue
Mon, Apr 14, 2025 10:44 CET Report this content
An investigator-initiated phase II study has been launched with SynAct Pharma’s lead candidate, resomelagon, in patie... |
| Mar 6, 2025 | BioStock: SynAct Pharma secures key US patent | BioStock: SynAct Pharma secures key US patent
Thu, Mar 06, 2025 09:19 CET Report this content
SynAct Pharma has been granted a pivotal US patent protecting the crystal form of resomelagon, a drug candidate currently in phase IIb clinical de... |
| Feb 19, 2025 | BioStock: SynAct Pharma advances trial with boosted funding | BioStock: SynAct Pharma advances trial with boosted funding
Wed, Feb 19, 2025 11:45 CET Report this content
In the fourth quarter, SynAct Pharma focused on progressing its Phase IIb study, ADVANCE, evaluating resomelagon in newly diagnosed ... |
| Nov 25, 2024 | Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors | ROCKVILLE, Md. and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily ... |
| Apr 2, 2024 | BioStock: Synact focuses on pushing forward rheumatoid arthritis project | BioStock: Synact focuses on pushing forward rheumatoid arthritis project
Tue, Apr 02, 2024 10:41 CET Report this content
SynAct Pharma is intent on making a turnaround after posting disappointing study results with lead asset resomelagon. T... |
| Dec 19, 2023 | Revolutionizing Inflammatory Disease Treatment: A New Era in Biotech Healthcare? | Today we explore the work of SynAct Pharma, an innovative biotech and healthcare startup from Lund, Sweden. Focused on the development of drugs for acute deterioration in inflammatory diseases, SynAct Pharma deploys groundbreaking approache... |
| May 29, 2023 | Find your next investment at the BioStock Life Science Spring Summit on May 30 and 31! | Find your next investment at the BioStock Life Science Spring Summit on May 30 and 31!
Mon, May 29, 2023 09:45 CET Report this content
It is finally time for BioStock Life Science Spring Summit 2023! Around 30 companies from a wide range of... |
| Jul 8, 2022 | SynAct Pharma AB publishes prospectus for list change to Nasdaq Stockholm | SynAct Pharma AB publishes prospectus for list change to Nasdaq Stockholm
Fri, Jul 08, 2022 09:45 CET Report this content
SynAct Pharma AB (“SynAct” or the “Company”) announced on June 28, 2022 that Nasdaq Stockholm’s listing committee has ... |
| Jun 29, 2022 | SynAct Pharma recieves pre-IND response from the US FDA | SynAct Pharma recieves pre-IND response from the US FDA
Wed, Jun 29, 2022 18:00 CET Report this content
SynAct Pharma AB (“SynAct”) today announced that the company was granted and has received written response from the US Food and Drug Adm... |
| Jun 28, 2022 | SynAct Pharma AB has been approved for listing on Nasdaq Stockholm | SynAct Pharma AB has been approved for listing on Nasdaq Stockholm
Tue, Jun 28, 2022 15:30 CET Report this content
Nasdaq Stockholm´s listing committee has today announced that it considers that SynAct Pharma AB (“SynAct” or the “Company”) ... |
| Jun 21, 2022 | SynAct Pharma submits CTA for Clinical Phase 2b Study in RA | SynAct Pharma submits CTA for Clinical Phase 2b Study in RA
Tue, Jun 21, 2022 07:00 CET Report this content
SynAct Pharma AB (“SynAct”) today announced that it has submitted a Clinical Trial Application (CTA) to initiate the clinical Phase ... |
| May 30, 2022 | SynAct Pharma publishes Q1 2022 interim report | SynAct Pharma publishes Q1 2022 interim report
Mon, May 30, 2022 07:00 CET Report this content
SynAct Pharma AB (publ) (“SynAct”) today publishes the interim report for the first quarter 2022.
“During the first quarter, we made important de... |
| May 20, 2022 | Bulletin from the annual general meeting in SynAct Pharma AB on May 20, 2022 | Bulletin from the annual general meeting in SynAct Pharma AB on May 20, 2022
Fri, May 20, 2022 14:00 CET Report this content
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the Englis... |
| May 18, 2022 | press release May 18 2022 Synact Pharma to present at the ABGSC Life Science Summit | press release May 18 2022 Synact Pharma to present at the ABGSC Life Science Summit
Wed, May 18, 2022 12:29 CET Report this content
Stockholm, Sweden — Synact Pharma AB (”SynAct” eller ”Bolaget”) today announces that the company will presen... |
| May 12, 2022 | Last day of trading in paid subscribed shares (Sw. betalda tecknade aktier) in SynAct Pharma AB | Last day of trading in paid subscribed shares (Sw. betalda tecknade aktier) in SynAct Pharma AB
Thu, May 12, 2022 08:00 CET Report this content
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STA... |
| May 4, 2022 | SynAct Pharma completes clinical pharmacokinetic test of AP1189 tablet | SynAct Pharma completes clinical pharmacokinetic test of AP1189 tablet
Wed, May 04, 2022 08:00 CET Report this content
SynAct Pharma AB (“SynAct”) today announce that the company´s pharmacokinetic study on new tablet formulations of AP1189 ... |
| Apr 29, 2022 | SynAct Pharma AB publishes Annual Report 2021 | SynAct Pharma AB publishes Annual Report 2021
Fri, Apr 29, 2022 09:00 CET Report this content
SynAct Pharma AB (“SynAct”) today announces that the Annual Report for 2021 is now available as a pdf on the group’s web page, www.synactpharma.co... |
| Apr 25, 2022 | SynAct announces outcome of rights issue | SynAct announces outcome of rights issue
Mon, Apr 25, 2022 20:45 CET Report this content
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NE... |
| Apr 20, 2022 | Notice of annual general meeting in SynAct Pharma AB | Notice of annual general meeting in SynAct Pharma AB
Wed, Apr 20, 2022 08:00 CET Report this content
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedi... |
| Apr 1, 2022 | SynAct publishes prospectus in connection with a fully guaranteed rights issue | SynAct publishes prospectus in connection with a fully guaranteed rights issue
Fri, Apr 01, 2022 14:59 CET Report this content
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, A... |
| Mar 28, 2022 | SynAct resolves on a fully guaranteed rights issue of approximately SEK 150 million | SynAct resolves on a fully guaranteed rights issue of approximately SEK 150 million
Mon, Mar 28, 2022 07:00 CET Report this content
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERI... |
| Mar 28, 2022 | Bulletin from the extraordinary general meeting on March 28, 2022, in SynAct Pharma AB | Bulletin from the extraordinary general meeting on March 28, 2022, in SynAct Pharma AB
Mon, Mar 28, 2022 14:00 CET Report this content
Today, on March 28, 2022, an extraordinary general meeting was held in SynAct Pharma AB. The meeting was ... |
| Mar 9, 2022 | Notice of extraordinary general meeting in SynAct Pharma AB | Notice of extraordinary general meeting in SynAct Pharma AB
Wed, Mar 09, 2022 08:00 CET Report this content
The shareholders in SynAct Pharma AB, Reg. No. 559058-4826 (“SynAct”), are hereby invited to the extraordinary general meeting to be... |
| Mar 9, 2022 | The Nomination Committee proposes Kerstin Hasselgren as a new board member of SynAct Pharma AB | The Nomination Committee proposes Kerstin Hasselgren as a new board member of SynAct Pharma AB
Wed, Mar 09, 2022 07:55 CET Report this content
The Nomination Committee of SynAct Pharma AB (“SynAct”) has informed the company that the Nominat... |
| Feb 11, 2022 | Annual Results 2021 | Annual Results 2021
Fri, Feb 11, 2022 07:00 CET Report this content
"Together we made incredible progress during 2021, setting the stage for what could be a transformative 2022. We will do our utmost to deliver continued shareholder an... |
| Jan 7, 2022 | SynAct Pharma appoints Patrik Renblad as CFO | SynAct Pharma appoints Patrik Renblad as CFO Fri, Jan 07, 2022 07:00 CET
SynAct Pharma AB (“SynAct”) today announced that Patrik Renblad has been appointed Chief Financial Officer (CFO). Patrik Renblad joined the group in August 2021 as Vic... |
| Dec 7, 2021 | SynAct Pharma’s board and management extend lock-up agreements | SynAct Pharma’s board and management extend lock-up agreements Tue, Dec 07, 2021 07:00 CET
SynAct Pharma AB (“SynAct”) today announced that all members of its board and management have signed lock-up agreements for their shares in the compa... |
| Dec 2, 2021 | SynAct Pharma announces additional data from the BEGIN study | SynAct Pharma announces additional data from the BEGIN study Thu, Dec 02, 2021 07:30 CET
SynAct Pharma AB (“SynAct”) today announced additional results on the secondary endpoints ACR50 and ACR70 from the Phase 2a study of AP1189 (BEGIN) in ... |
| Dec 1, 2021 | SynAct Pharma strengthens its patent portfolio for AP1189 following an Intention to Grant from the European Patent Office | SynAct Pharma strengthens its patent portfolio for AP1189 following an Intention to Grant from the European Patent Office Wed, Dec 01, 2021 07:00 CET
SynAct Pharma AB (“SynAct”) today announced that the European Patent Office (EPO) has issu... |
| Nov 30, 2021 | SynAct Pharma’s AP1189 meets primary endpoint and demonstrates favorable safety profile in Rheumatoid Arthritis patients with active joint disease in the Phase 2a BEGIN study | SynAct Pharma’s AP1189 meets primary endpoint and demonstrates favorable safety profile in Rheumatoid Arthritis patients with active joint disease in the Phase 2a BEGIN study Tue, Nov 30, 2021 03:08 CET
SynAct Pharma AB (“SynAct”) today ann... |
| Nov 23, 2021 | SynAct Pharma reports positive PK data on AP1189 tablets | SynAct Pharma reports positive PK data on AP1189 tablets Tue, Nov 23, 2021 07:00 CET
SynAct Pharma AB ("SynAct") today announced that it has received positive data from the first part of the ongoing pharmacokinetic (PK) study of A... |
| Nov 19, 2021 | SynAct Pharma announces Nomination Committee in respect of AGM 2022 | SynAct Pharma announces Nomination Committee in respect of AGM 2022 Fri, Nov 19, 2021 07:00 CET
SynAct Pharma AB (“SynAct”) today announced that the Nomination Committee in preparation for the Annual General Meeting 2022 on May 20, 2022, ha... |
| Nov 12, 2021 | Interim report Q3 2021 | Interim report Q3 2021 Fri, Nov 12, 2021 07:00 CET
"The third quarter was another productive period for SynAct Pharma, both from an R&D perspective but also in terms of preparing the company for the intense work ahead and ensuring ... |
| Nov 11, 2021 | SynAct Pharma takes advantage of new toxicology results and new tablet formulation to re-design and optimize the study programme with AP1189 in Nephrotic Syndrome | SynAct Pharma takes advantage of new toxicology results and new tablet formulation to re-design and optimize the study programme with AP1189 in Nephrotic Syndrome Thu, Nov 11, 2021 07:30 CET
SynAct Pharma today announces that the company in... |
| Nov 5, 2021 | AP1189 can be dosed for three months in future clinical studies | AP1189 can be dosed for three months in future clinical studies Fri, Nov 05, 2021 07:00 CET
SynAct Pharma AB ("SynAct") today announced that the company successfully has completed preclinical toxicology studies aimed to support 3 ... |
| Oct 15, 2021 | SynAct Pharma doses first subject in study with new AP1189 tablets | SynAct Pharma doses first subject in study with new AP1189 tablets Fri, Oct 15, 2021 15:34 CET
SynAct Pharma AB (“SynAct”) today announced that the first subject has been dosed in a clinical study in healthy volunteers to describe the pharm... |
| Aug 27, 2021 | SynAct Pharma Provides an Update on Patient Recruitment in the Phase 2a Clinical Trial of AP1189 in Rheumatoid Arthritis | SynAct Pharma Provides an Update on Patient Recruitment in the Phase 2a Clinical Trial of AP1189 in Rheumatoid Arthritis Fri, Aug 27, 2021 01:06 CET
SynAct Pharma AB (“SynAct”) today announced that recruitment in the BEGIN study in Rheumato... |
| Aug 27, 2021 | SynAct Pharma: Interim Report January-June 2021 August 27, 2021 | SynAct Pharma: Interim Report January-June 2021 August 27, 2021 Fri, Aug 27, 2021 08:30 CET
“Positive data of AP1189 in Covid-19 patients bodes well for the future. The hard work at the start of the year continued in the second quarter as S... |
| Aug 27, 2021 | SynAct Pharma: Interim Report January-June 2021 August 27, 2021 (Q2 2021 Report included) | SynAct Pharma: Interim Report January-June 2021 August 27, 2021 (Q2 2021 Report included) Fri, Aug 27, 2021 08:54 CET
“Positive data of AP1189 in Covid-19 patients bodes well for the future. The hard work at the start of the year continued ... |
| Aug 25, 2021 | SynAct strengthens IP portfolio – Grant of key European patent covering AP1189 | SynAct strengthens IP portfolio – Grant of key European patent covering AP1189 Wed, Aug 25, 2021 09:54 CET
SynAct Pharma AB ("SynAct") today announced that a European patent was granted covering the company’s leading drug candidat... |
| Aug 20, 2021 | SynAct Pharma to present new data on AP1189 for the treatment of rheumatoid arthritis at ACR Convergence 2021 | SynAct Pharma to present new data on AP1189 for the treatment of rheumatoid arthritis at ACR Convergence 2021 Fri, Aug 20, 2021 08:30 CET
SynAct Pharma AB (“SynAct”) today announced that an abstract entitled ”AP1189: A Novel Oral Biased Mel... |
| Aug 6, 2021 | SynAct Pharma strengthens its organization with two key recruitments | SynAct Pharma strengthens its organization with two key recruitments Fri, Aug 06, 2021 09:59 CET
SynAct Pharma AB (“SynAct”) today announced the appointments of Patrik Renblad as Vice President Finance and Lise Agersted as Director of Opera... |
| May 21, 2021 | Bulletin from the annual general meeting in SynAct Pharma AB on 21 May 2021 | Bulletin from the annual general meeting in SynAct Pharma AB on 21 May 2021 Fri, May 21, 2021 12:00 CET
Today, on 21 May 2021, the annual general meeting was held in SynAct Pharma AB. In light of the ongoing Covid-19 pandemic and in order t... |
| May 4, 2021 | SYNACT PHARMA AB
SynAct Pharma : expands AP1189 BEGIN study in Rheumatoid Arthritis UK Version | Lund, Sweden, May 4, 2021. SynAct Pharma AB ("SynAct") today announced that based upon the encouraging results seen in part 1 of the phase 2 clinical study BEGIN of AP1189, the company has decided to increase the study size in an ... |
| Nov 9, 2020 | SynAct : Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritis | The Data Safety Monitoring Board (DSMB) finds no safety concerns in the 50 mg and 100 mg dose cohorts
Signs of efficacy against rheumatoid arthritis was observed. Thus, the number of patients changing from the severe to the moderate Clinica... |
